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ABSTRACT

Objective Depression is common in individuals with
chronic cutaneous lupus erythematosus (CCLE). However,
how CCLE may impact patients’ psychological well-being
is poorly understood, particularly among disproportionally
affected populations. We examined the relationships
between depression and psychosocial factors in a cohort
of predominantly Black patients with primary CCLE (CCLE
without systemic manifestations).
Methods Cross-sectional assessment of individuals with
dermatologist-validated diagnosis of primary CCLE. NIH-
PROMIS short-forms were used to measure depression,
disease-related stigma, social isolation and emotional
support. Linear regression analyses (ɑ=0.05) were used
to test an a priori conceptual model of the relationship
between stigma and depression and the effect of social
isolation and emotional support on that association.
Results Among 121 participants (87.6% women;
85.1% Black), 37 (30.6%) reported moderate
to severe depression. Distributions of examined
variables divided equally among those which did (eg,
work status, stigma (more), social isolation (more),
emotional support (less)) and did not (eg, age, sex,
race, marital status) significantly differ by depression.
Stigma was significantly associated with depression
(b=0.77; 95% CI0.65 to 0.90), whereas social isolation
was associated with both stigma (b=0.85; 95% CI
0.72 to 0.97) and depression (b=0.70; 95% CI0.58
to 0.92). After controlling for confounders, stigma
remained associated with depression (b=0.44; 95%
CI0.23 to 0.66) but lost significance (b=0.12; 95%
CI −0.14 to 0.39) when social isolation (b=0.40;
95% CI 0.19 to 0.62) was added to the model. Social
isolation explained 72% of the total effect of stigma
on depression. Emotional support was inversely
associated with depression in the univariate analysis;
however, no buffer effect was found when it was
added to the multivariate model.
Conclusion Our findings emphasise the psychosocial
challenges faced by individuals living with primary
CCLE. The path analysis suggests that stigmatisation
and social isolation might lead to depressive
symptoms. Early clinical identification of social
isolation and public education demystifying CCLE
could help reduce depression in patients with CCLE.

WHAT IS ALREADY KNOWN ON THIS TOPIC
⇒ Discoid lupus erythematosus (DLE) and other chron-

ic cutaneous lupus erythematosus (CCLE) conditions
often cause substantial skin disfigurement, which
may have a negative impact on patients’ mental
health. These conditions are less likely to overlap
with systemic manifestations, compared with other
cutaneous lupus erythematosus (CLE) types, and
people with black or brown skin are disproportionately affected by DLE. However, the burden of depression and its psychosocial pathways are poorly
understood in individuals with CCLE, particularly
among those from minority groups that have primary
CCLE without systemic manifestations.
WHAT THIS STUDY ADDS
⇒ Our study establishes that approximately one-third

of participants in a cohort of predominantly Black
patients with primary CCLE self-reported moderate
to severe depression. Findings suggest that disease-
related stigma and social isolation may play important roles in depression pathways among these
patients. Emotional support did not show a significant buffer effect, suggesting that depression may
have profound roots in social detachment, which, in
turn, may be driven by internalised stigma.
HOW THIS STUDY MIGHT AFFECT RESEARCH,
PRACTICE OR POLICY
⇒ Our findings underscore the importance of increased

clinical attention to diagnosis and management of
depression among patients with CCLE as well as
suggesting additional intervention points that might
prevent depression from occurring. Early identification of patients experiencing social isolation and social stigma, combined with effective interventions to
address these factors could potentially prevent these
patients from deeper social withdrawal and development of depression. Additionally, public health
campaigns that raise awareness about these potentially disfiguring conditions may help to reduce the
social stigma and mitigate the psychosocial impact
of CCLE on affected individuals.
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Figure 1 Conceptual model of the study. We examined the
relationship between stigma (main exposure) and depression
(outcome) after controlling for covariates. Social isolation was
evaluated as a potential mediator of the stigma-depression
relationship, and emotional support as a potential buffer. In
addition, we analysed the association of skin activity and
skin damage on depression in a subset of participants. DLE,
discoid lupus erythematosus.

INTRODUCTION
Cutaneous lupus erythematosus (CLE) is a group of
autoimmune disorders categorised into acute, subacute
(SCLE) and chronic (CCLE) cutaneous lupus erythematosus.1
CCLE is the largest subgroup, with conditions prone to
cause substantial disfigurement on visible skin, negatively
impacting patients’ mental health and social life. Classical
discoid lupus erythematosus (DLE), the most common
distinctive CCLE form, is characterised by lesions largely
localised on the scalp and face that heal causing skin
dyspigmentation, atrophy, scarring and permanent hair
loss.1–3 Furthermore, DLE lesions are more likely to be
noticeable in people with black or brown skin, a population that is disproportionately affected by this condition
and has an earlier onset of skin damage relative to Whites.4
In metropolitan Atlanta, where the population is evenly
distributed between Whites and Blacks, we reported the
overall incidence rate of CCLE and DLE at a minimum of
3.9/100 000 and 3.7/100 000 person years, respectively.5
CCLE and DLE incident rates were 3.9-fold and 4.1-fold
higher for Blacks compared with Whites, respectively.
Healthy People 2030, the nation’s health objectives,
addresses the prevention, screening, assessment and treatment of mental disorders and behavioural conditions,
acknowledging that some populations are disproportionately affected by mental illnesses.6 Clinical conditions that
have skin manifestations increase the risk of depression.7
Notably, the emotional impact of having a cutaneous
disorder was found to be significantly higher in patients
with CLE compared with other skin diseases.8 Depression is described in over one-
quarter of patients with
CLE, and healthcare costs in this population are substantially higher among those with depression.9 10 However,
mental health challenges are often underdiagnosed
among patients with CLE, and little is known about the
mechanisms that lead to depression in this population.11
Because most studies have included patients with all types
2

of CLE and overlapping systemic lupus erythematosus
(SLE), the burden and pathways of depression remain
poorly understood among those with primary CCLE.
Stigma is defined by the WHO as ‘a mark of shame,
disgrace or disapproval which results in an individual
being rejected, discriminated against, and excluded from
participating in a number of different areas of society’.
Stigma plays a role in depression for conditions as diverse
as psoriasis, HIV, epilepsy and mental illnesses.12–15
Internalised shame and perceived stigma correlate with
depression, and stigma has been linked to social isolation
and other maladaptive responses, increasing the risk of
poor mental health outcomes.12 13 16
In patients with SLE, both cutaneous involvement and
stigma were found to be associated with depression,8 and
stigma has contributed to low self-esteem and isolation
from social activities in this population.17 We previously
reported a 26% prevalence of moderate to severe depressive symptoms in a predominantly Black population-based
cohort of patients with primary CCLE.18 Our work also
underscored an inverse association between emotional
support and depression, suggesting that social factors
play a role in the pathogenesis of depression among
individuals with CCLE.18 Despite the high prevalence of
depression in patients with CLE in general and CCLE in
particular, sparse literature explores psychosocial pathways in high-risk populations with primary CCLE.
Understanding the relationships between stigma, social
isolation, emotional support and depression is critical to
developing interventions that facilitate non-stigmatising
awareness and reduce stigma stress among people with
CCLE. The inclusion of Black individuals, who are disproportionately stricken by CCLE, have worse outcomes,
and have been historically underrepresented in lupus
research is imperative to develop these interventions.
We examined the relationships between depression and
illness-related stigma in a cohort of predominantly Black
patients with primary CCLE using descriptive statistics.
Additionally, we explored the role of social isolation and
emotional support in that relationship by testing an a
priori path derived from a novel conceptual model of
stigma in visible skin diseases (figure 1).19 Specifically, our
objectives were to: (1) establish the independent association between stigma and depression, (2) test for potential
mediation of this relationship through social isolation
and (3) test for moderation of this relationship by degree
of emotional support.
METHODS
Population
Georgians Organized Against Lupus (GOAL) is a
population-
based cohort of predominantly Black individuals with dermatologist-validated lupus supported by
the Centers for Disease Control and Prevention (CDC).
Its overall aim is to examine the impact of social determinants of health outcomes relevant to patients, healthcare providers and policy makers. Recruitment and data
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collection methods have been previously described.20
Briefly, GOAL initially recruited patients with SLE from the
Georgia Lupus Registry (GLR). The GLR is a population-
based registry funded by CDC to estimate the incidence
and prevalence of SLE in Atlanta, Georgia, where there is
a large, socioeconomically diverse Black/White population.21 22 In 2015, GOAL received CDC funding to enrol
patients with CCLE or SCLE. Sources of recruitment have
been the GLR, community and academic dermatology
practices, and self-referrals through the Lupus Foundation of America, Georgia Chapter.
For this cross-sectional study, we selected GOAL participants with primary CCLE through a diagnosis validation
process including medical records review, physician-
assessment and review of pictures. Classification of CCLE
required either a well-
documented diagnosis of DLE,
lupus panniculitis (LEP), lupus tumidus (LET) or chilblain lupus (ChLE) by a board-certified dermatologist
or a skin-
examination±photographs compatible with
CCLE subtypes according to a study dermatologist’s (LA)
review. To focus on primary CCLE, we excluded those
participants with a rheumatologist-documented diagnosis
of SLE and/or those who fulfilled ≥4 American College
of Rheumatology criteria for SLE.23 The Emory University Institutional Review Board, the Grady Health System
Research Oversight Committee and the Georgia Department of Public Health Review Board approved the study.
All participants provided informed consent.
Patient and public involvement
We convened a diverse group of GOAL participants into
the Lupus Patient Advisory Research Council (L-PARC);
members meet at least once a year with researchers to
provide advice on recruitment, retention, study measures
and dissemination of findings.
Measures
Patient-reported responses collected from March 2020
through September 2021 were analysed. Patient-Reported
Outcomes Measurement Information System (PROMIS)
adult short forms were used to measure depression, social
isolation, emotional support and overall physical health,
and the Neuro-QoL system was used to assess generic
disease-related stigma. These measures have been validated in patients with a variety of chronic conditions,
including rheumatic diseases and lupus, and are recommended for use because of their flexibility and precision.24–26 Each tool uses a 5-point Likert scale. Raw scores
were individually calculated and converted to T-scores by
the HealthMeasures Scoring ServiceSM,27 which rescales
the raw score into a standardised score with a mean of
50 and a SD of 10. Higher scores represent more of the
domain being measured.
Depression
We used the PROMIS Depression short form 8a,
comprising 8 Likert-scale questions rated from 1 (never)
to 5 (always) to assess negative mood (eg, sadness, guilt),

views of self (eg, self-
criticism, worthlessness), social
cognition (eg, loneliness) and decreased positive affect
and engagement (eg, loss of interest) in the past 7 days.
Self-reported depression was defined as a T-score ≥60,
corresponding with the analogous Patient Health Questionnaire 9 (PHQ-9) scores.28 29 This PROMIS scale has
been extensively validated and was adopted by the Diagnostic and Statistical Manual of Mental Disorders (5th
ed.; DSM-5) as a standardised patient-reported scale that
can contribute to psychiatric diagnosis, tracking of illness
course and treatment planning.30 31 PROMIS Depression
showed strong convergent validity with the CES-D and
the PHQ-9 (with correlations in a range from 0.72 to 0.84
across three time points).32
Stigma
The Neuro-QoL Stigma short form 8 was used to evaluate
negative perceptions of self (eg, embarrassment), publicly
enacted negativity (eg, people’s unkindness, discomfort,
embarrassment) and discrimination (eg, being avoided,
left out, blamed) as a result of disease-related manifestations.33 The scale has demonstrated high internal consistency, test-
retest reliability and convergent correlations
with expected legacy measures.34
Social isolation
We used the PROMIS Social Isolation short form 8a, rated
from 1 (never) to 5 (always), to assess perceptions of loneliness, being avoided, excluded, detached, disconnected
from or unknown by others. The scale has demonstrated
very good internal consistency reliability, with Cronbach’s
alpha=0.860.35
Emotional support
The PROMIS Emotional Support short form 4a was used
to assess perceived feelings of being cared for and valued
as a person and having confidant relationships.
Sociodemographic covariates
Self-
reported data on sociodemographics that may be
associated with depression included age, sex, race/
ethnicity, years of education, marital status, employment
and living below the poverty level (calculated using the
U.S. Census Bureau’s 2011 estimates as cut-off for 100%
poverty threshold.36
Disease-related covariates
Distribution of DLE lesions was determined by clinical
assessment or medical record review and classified as
being localised (above the neck) or generalised (above
and below the neck).1 Skindex 29+3, a validated skin-
specific quality of life instrument for people with CLE,
was used to assess the severity of cutaneous symptoms (eg,
itching, burning, irritation), the impact of the condition
on functioning (eg, relationships, work, sleeping) and
a lupus-specific domain (eg, limited outdoor activities,
worried about hair loss, worried about flares related to
sun exposure).37 38 The Skindex emotions scale was not
analysed because it includes several questions about
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depression. Scores for each Skindex domain range from
0 to 100, with 100 indicating a poorer quality of life. In
addition, we collected self-reported data on disease duration and treatment, including hydroxychloroquine or
other antimalarial drugs, local steroids (topical or intralesional), systemic steroids and/or immunosuppressive
drugs (oral or intravenous).
A subset of 59 participants were also evaluated with
the Cutaneous Lupus Erythematosus Disease Area and
Severity Index (CLASI), a validated physician-
based
measure to score the severity of cutaneous lupus.39 Separate CLASI activity and CLASI damage scores were calculated, with higher scores (range 0–70 for activity and 0–56
for damage) indicating more severe disease.
Global physical health was measured using the PROMIS
Global-
10 SF, a high-
reliability scale to assess physical
health, physical function, pain and fatigue.40 41
Statistical analysis
Descriptive statistics were calculated to characterise the
sample overall and among those with and without depression. Distributions for categorical variables were generated as number and per cent; continuous variables were
expressed as mean and SD.
Figure 1 illustrates the conceptual model used to guide
the path analysis. Linear regression was used to examine
the relationship between stigma (main exposure), social
isolation (potential mediator) and emotional support
(potential moderator) with depression (outcome). The
mediator effect of the stigma-
depression relationship
was tested using the four steps outlined by Baron and
Kenny (online supplemental table 1).42 The first step was
conducted through linear regression analysis to examine
the relationship between stigma and depression. We
then regressed separately social isolation on stigma and
depression on social isolation (steps 2 and 3).
Multivariable regression was used to determine whether
the association between stigma and depression remained
significant after controlling for sociodemographics and
disease-related covariates, which were entered in blocks
(depicted in online supplemental table 3, Models 1
and 2, respectively). For the fourth step of Baron and
Kenny (online supplemental table 1), stigma and social
isolation were tested simultaneously, controlling for all
other covariates (online supplemental table 3, Model 3).
Per this approach, mediation was established if the first
three steps were shown to be significant, and the effect of
stigma on depression was reduced when social isolation
was entered in the model. Then, we estimated the extent
to which social isolation contributed to the total effect
of stigma on depression after adding emotional support
(online supplemental table 3, Model 4) and performed
the Sobel’s z-test on the significance of the mediation
effect.43 Finally, we tested whether emotional support had
a moderation effect on the association between depression
and stigma by entering the interaction term stigma*emotional support. We built two final models by including and
excluding the DLE subtype covariate, thus testing both
4

the DLE sample (table 3, Model 1) and the whole CCLE
sample (table 3 Model 2), respectively. We used R2 to
measure the percentage of the variance in depression
explained by all variables in each model and conducted
posthoc tests of normality of residuals, heteroskedasticity,
linearity and multicollinearity. We found no evidence for
influential observations or outliers. We separately analysed participants with CLASI data to assess whether skin
activity and skin damage were associated with depression.
Statistical significance was set at ɑ=0.05 for descriptive
analyses and non-overlapping 95% CI for regression analyses. All analyses were conducted in SAS V.9.4.
RESULTS
We evaluated responses from 121 GOAL participants
who had a documented diagnosis of primary CCLE
(87.6% women and 85.1% self-identified as being Black).
Of those, 109 had DLE (13 with another CCLE subtype)
and 12 had other CCLE subtypes (LEP=5, LET=5,
ChLE=2). DLE lesions were localised in 74 participants,
generalised in 34 and 1 participant had missing data on
location. Except for a higher proportion of Black individuals among those with DLE (89.9%) compared with those
with other CCLE subtypes (41.7%), sociodemographics,
psychological factors and disease-
related factors were
similar between both groups.
Thirty-seven (30.6%) participants reported moderate
to severe depressive symptoms (PROMIS Depression
T-score≥60). Descriptive characteristics for the overall
sample and by depression status are shown in table 1.
Mean age and disease duration were 54.1 (SD=13.8) and
14.2 (SD=10.0) years, respectively. No statistically significant differences by depression were observed for age, sex,
race, marital status, insurance or disease duration. Participants with depression had significantly less years of education (mean=13.4, SD=2.6) compared with those without
depression (mean=15.0, SD=3.2). Nearly 60% combined
were either unemployed/disabled (31.9%) or out of the
labour force (26.7%), while 41.4% were working either
full-time or part-time. Employment status differed significantly by depression, with 51.4% of depressed participants
being unemployed or disabled, compared with 23.5% of
those without depression.
For all three psychosocial factors, those with depression
had significantly worse values than those without: more
stigma (mean=60.9 vs mean=47.0); more social isolation
(mean=59.5 vs mean=45.6); lower emotional support
(mean score=47.8 vs mean=53.3).
For disease-related factors, among the subgroup with
DLE (n=108), generalised lesions occurred in 50% of
depressed, compared with 23.7% of non-
depressed,
participants, p=0.012. Compared with participants
without depression, depressed participants had significantly higher (worse) scores of Skindex symptoms
(mean=59.2 vs mean=35.3), functioning (mean=57.8 vs
mean=21.2) and the CLE-related domain (mean=83.6 vs
mean=52.4).
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Table 1 Description of the CCLE sample, overall and by depression
Characteristic

Indicator n (%) unless otherwise indicated

Overall (n=121)

Without depression (n=84)

With depression (n=37)

P value

Age (years)

Mean±SD

Sex

Male

54.1±13.8

55.2±14.9

51.7±10.8

0.20

15 (12.4)

11 (13.1)

4 (10.8)

0.73

Female

106 (87.6)

73 (86.9)

33 (89.2)

Black

103 (85.1)

70 (83.3)

33 (89.2)

White

18 (14.9)

14 (16.7)

4 (10.8)

Hispanic

6 (5.0)

4 (4.8)

2 (5.6)

Non-Hispanic

114 (95.0)

80 (95.2)

34 (94.2)

Mean±SD

14.5±3.1

15.0±3.2

13.4±2.6

0.009
0.27

Sociodemographic factors

Race

Ethnicity

Education (years)
Marital status

0.4

0.85

Currently married*

38 (31.4)

30 (35.7)

8 (21.6)

Ever married

43 (35.5)

29 (34.5)

14 (37.8)

Never married

40 (33.1)

25 (29.8)

15 (40.5)

Employed

48 (41.4)

38 (46.9)

10 (28.6)

Out of labour force

31 (26.7)

24 (29.6)

7 (20.0)

Unemployed/disabled

37 (31.9)

19 (23.5)

18 (51.4)

No insurance

21 (17.6)

15 (18.1)

6 (16.7)

Federal insurance

62 (51.2)

41 (48.8)

21 (56.8)

Private insurance

36 (30.3)

27 (32.5)

9 (25.0)

Stigma†

Mean±SD

51.3±10.4

47.0±8.1

60.9±8.2

<0.001

Social isolation†

Mean±SD

49.8±11.3

45.6±9.6

59.5±8.7

<0.001

Emotional support†

Mean±SD

51.7±8.9

53.3±8.8

47.8±8.1

0.002

Disease duration (years)

Mean±SD

14.2±10.0

13.8±9.6

15.1±11.0

0.52

DLE subtype‡

Localised

74 (68.5)

58 (76.3)

16 (50.0)

0.012

Generalised

34 (31.5)

18 (23.7)

16 (50.0)

 Symptoms

Mean±SD

42.7±24.6

35.3±22.8

59.2±20.3

<0.001

 Functioning

Mean±SD

32.5±27.0

21.2±20.4

57.8±22.6

<0.001

 CLE domain

Mean±SD

61.8±28.5

52.4±27.3

83.6±17.4

<0.001

 Skin activity

Mean±SD

4.5±4.6

4.0±4.6

5.2±4.7

0.36

 Skin damage

Mean±SD

12.7±7.9

12.1±8.2

13.6±7.5

0.47

Physical health†

Mean±SD

41.5±10.3

44.9±9.5

33.9±7.8

<0.0001

No

49 (40.5)

42 (50.0)

7 (18.9)

0.001

Yes

72 (59.5)

42 (50.0)

30 (81.1)

No

60 (49.6)

41 (48.8)

19 (51.4)

Yes

61 (50.4)

43 (51.2)

18 (48.6)

No

95 (78.5)

66 (78.6)

29 (78.4)

Yes

26 (21.5)

18 (21.4)

8 (21.6)

Work status

Insurance status

0.012

0.27

Psychosocial factors

Disease-related factors

Skindex 29+3

CLASI§

Current treatment
Hydroxychloroquine

Local steroids
Systemic steroids and/or
immunosuppressors

0.80
0.98

Depression was measured with the PROMIS Depression short form 8a; a T-score≥60 was used to define depression.
*Includes ‘living with a partner’.
†For PROMIS and Neuro-QoL measures, raw scores were converted to T-scores by the PROMIS HealthMeasures Scoring Service; higher scores indicate more of the domain being
assessed.
‡Assessment of 108 participants with DLE (1 patient had missing data on DLE location).
§CLASI was measured in 59 participants (36 without depression and 23 with depression).
CCLE, chronic cutaneous lupus erythematosus; CLASI, The Cutaneous Lupus Erythematosus Disease Area and Severity Index; DLE, discoid lupus erythematosus; PROMIS, Patient-
Reported Outcomes Measurement Information System.

Overall mean score for physical health was 41.4; patients
with depression reported significantly worse physical
health (mean=34.5) compared with those without

depression (mean=44.9). Over half (59.5%) of participants were on hydroxychloroquine, 50.4% reported treatment with local steroids and 21.5% were on oral steroids
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Table 2 Linear regression of depression on stigma, social isolation and emotional support
Unadjusted

Adjusted*

Exposure

b coefficient

95% CI

b coefficient

95% CI

Stigma
Social isolation
Emotional support

0.77
0.7
−0.45

0.65 to 0.90
0.58 to 0.82
−0.65 to −0.25

0.44
0.47
−0.11

0.23 to 0.66
0.31 to 0.63
−0.32 to 0.07

*Adjusted by sociodemographics (age, sex, race, education, marital status and work status), disease-related covariates (physical health and
DLE location), Skindex symptoms and Skindex CLE domain and medical treatment (Hydroxychloroquine, local steroids, systemic steroids
and/or immunosuppressive drugs). Depression, emotional support and social isolation were measured with the corresponding PROMIS Short
Form and stigma with the Neuro-QoL Stigma Short Form. Raw scores were converted to T-scores by the PROMIS HealthMeasures Scoring
Service; higher scores indicate more of the domain being assessed.
b, beta coefficient; CLE, cutaneous lupus erythematosus; PROMIS, Patient-Reported Outcomes Measurement Information System.

or immunosuppressive drugs. A significantly higher
proportion of depressed participants (81.1%) were on
hydroxychloroquine, compared with non-
depressed
(50%); no statistically significant differences were found
for other treatments by depression.
Among 59 participants with CLASI, overall mean scores
were 4.5 for activity and 12.7 for damage, respectively, and
did not differ by depression. We did not find a significant linear association between either skin activity or skin
damage scores and depression (online supplemental
figures 1 and 2). CLASI-assessed participants were more
likely to be Black and uninsured, compared with others,
but remaining demographics, in addition to depression,
stigma, social isolation and emotional support scores
were similar between both groups (online supplemental
table 2).
The relationships between psychosocial exposures
and depression are shown in table 2. Stigma and social
isolation were significantly associated with higher depression (b=0.77; 95% CI 0.65 to 0.90 for stigma, and b=0.70;
95% CI 0.58 to 0,82 for social isolation), whereas the
slope of depression decreased significantly with higher
emotional support (b=−0.45; 95% CI −0.65 to –0.25).
To examine the potential mediation effect of social
isolation, social isolation was regressed on stigma (step 2
of Baron and Kenny), showing a statistically significantly
association (b=0.85; 95% CI0.72 to 0.97).
Our hypothesis that there was a significant direct association between stigma and depression was supported
by the multivariate regression analysis (online supplemental table 3, Model 1: b=0.75; 95% CI 0.62 o 0.89,
after controlling for sociodemographics). Disease-
related covariates were then added as a block for further
controlling. The Skindex functioning domain was not
included due to the multicollinearity with stigma (variance inflations (VIF)>5). The slope of depression
regressed on stigma decreased; however, the association
remained significant (online supplemental table 3, Model
2: b=0.44; 95% CI 0.23 to 0.66).
We then tested together stigma and social isolation,
after controlling for covariates. In this model, the adjusted
slope of depression regressed on social isolation slightly
decreased, but the association remained statistically
6

significant (online supplemental table 3, Model 3: b=0.40;
95% CI 0.19 to 0.62). Moreover, the effect of stigma on
depression was reduced from b=0.44 (95% CI 0.23 to
0.66) to b=0.12 (95% CI −0.14 to 0.39) and was no longer
significant, supporting a mediation effect of social isolation in the multivariate model (online supplemental table
3, Model 4). Sobel’s z-test rendered a significant mediation effect with 71.4% and 72% (p<0.001) of the total
effect of stigma being mediated by social isolation after
controlling for sociodemographic and disease covariates
(online supplemental table 3, Models 3 and 4).
Our hypothesis that emotional support would have a
moderating effect on the relationship between social
isolation and depression was not supported. Emotional
support was negatively associated with depression, but the
association was not statistically significant (online supplemental table 3, Model 4: b=−0.00; 95% CI −0.17 to 0.17).
The effect of each social isolation (b=0.40; 95% CI 0.19
to 0.62) and stigma (b=0.12; 95% CI −0.14 to 0.39) on
depression did not change when emotional support was
added to the model. Furthermore, we added the interaction term emotional support*stigma (table 3, Model 1),
confirming that emotional support did not have a significant effect (b=0.01; 95% CI −0.01 to 0.03). The effect of
social isolation on depression remained statistically significant with a similar slope (b=0.38; 95% CI 0.16 to 0.60)
after adding the interaction. When we tested the final
model in the whole CCLE sample, the results remained
similar after excluding the DLE subtype covariate (table 3,
Model 2).
Depression scores were directly associated with never
married (vs currently married) and inversely associated
with better physical health showing statistically significant
p values in all multivariate models. Variables in Models 3,
4 and 5 explained 72% of the variance for depression, as
indicated by R2 values.
DISCUSSION
Our findings demonstrated a significant association
between stigma and depression in patients with primary
CCLE. Path analysis indicates that the association diminished significantly but did not disappear when social
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Table 3 Multivariate regression models of depression by stigma, social isolation and emotional support
Model 1

Model 2

Factor

b (95% CI)

b (95% CI)

Primary exposures
 Stigma

−0.30 (−1.20 to 0.60)

−0.27 (−1.13 to 0.59)

 Social isolation

0.38 (0.16 to 0.60)

0.37 (0.18 to 0.57)

 Emotional support

−0.44 (−1.35 to 0.47)

−0.42 (−1.29 to 0.44)

 Stigma*Emotional support

0.01 (−0.01 to 0.03)

0.01 (−0.01 to 0.02)

 Sex (ref: male)

−1.65 (−5.72 to 2.43)

−1.74 (−5.54 to 2.06)

 Race (ref: white)

1.76 (−2.84 to 6.37)

1.23 (−2.29 to 4.74)

 Age at survey (years)

0.07 (−0.07 to 0.22)

0.05 (−0.07 to 0.17)

 Education (years)

0.34 (−0.18 to 0.85)

0.30 (−0.18 to 0.77)

  
Ever married

1.42 (−2.44 to 5.29)

1.24 (−2.25 to 4.74)

  
Never married

5.06 (1.55 to 8.58)

3.91 (0.69 to 7.13)

  Out of labour force

−2.24 (−6.35 to 1.86)

−2.56 (−6.24 to 1.11)

  
Unemployed/disabled

0.14 (−3.44 to 3.72)

−0.12 (−3.39 to 3.15)

−0.72 (−3.85 to 2.41)

–

Covariates
Sociodemographics

 Marital status (ref: currently married)

 Work status (ref: employed)

Disease-related factors
 DLE subtype (ref: below the neck)
  Above and below the neck
 Skindex 29+3
  
Symptoms

0.04 (−0.04 to 0.13)

0.05 (−0.03 to 0.12)

  
CLE domain

0.04 (−0.04 to 0.12)

0.03 (−0.04 to 0.09)

 Physical health (T-score)

−0.29 (−0.51 to 0.08)

−0.27 (−0.46 to 0.08)

  
Hydroxychloroquine

1.53 (−1.43 to 4.49)

1.86 (−0.82 to 4.55)

  
Local steroids

−0.09 (−3.08 to 2.90)

0.41 (−2.31 to 3.13)

  
Systemic steroids/immunosuppressors
(R-Square)

−1.54 (−5.09 to 2.02)
0.723

−1.78 (−5.03 to 1.47)
0.729

 Current treatment

Model 1 was tested among 101 participants with DLE and Model 2 among 113 participants with any CCLE subtype; 8 DLE participants had
missing data on 1 or more variables. Bolded values indicate statistical significance (95% CI no crossing 0).
b, beta coefficient; CCLE, chronic cutaneous lupus erythematosus; CLE, cutaneous lupus erythematosus; DLE, discoid lupus erythematosus.

isolation was included in the model. Therefore, social
isolation may partially mediate the relationship between
depression and stigma, which presents additional valuable up-stream intervention opportunities.
CCLE disproportionately strikes women and Black
individuals and typically starts at young ages.5 Individuals with these conditions suffer from changes in their
physical appearance, with scarring lesions predominantly
located on the scalp, face and hands, leading to high
levels of psychological distress as these visible lesions are
not easily covered.2 44 Psychological health is one of the
most negatively impacted domains in the quality of life of
patients with CLE.8 45 46 A recent study that used administrative data from a household sample in the U.S. Medical

Expenditure Panel Survey estimated a 29.5% prevalence
of depression among people with CLE.10 Likewise, the
risk of depression was found to be twofold higher in
people with CLE compared with the general population
in a nationwide Danish study.9
In this predominantly Black population-based cohort,
approximately one-
third of participants with primary
CCLE self-reported moderate to severe depression. Moreover, we found a direct relationship between depression
and a non-
specific measure of illness-
related stigma,
suggesting that depression can be primarily driven by
negative perceptions of self and discrimination as a
result of the disease. Perceptions of stigmatisation have
been significantly related to both psychological distress
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and degree of disability among patients with other skin
conditions.47
Our conceptual model was supported by statistically
significant evidence consistent with our hypothesis that
social isolation may be an important mediator in the relationship between stigma and depression in individuals
with CCLE. Prior reports suggest that social withdrawal
is a major effect of internalised stigma in individuals with
skin and other stigmatising conditions.15 Stigma caused by
altered skin appearance and, possibly, the need to avoid
the outdoors because of photosensitivity, predispose CCLE
to be a socially isolating disease.2 4 45 48 49 However, little
is known about the link between stigma, social isolation
and depression in skin conditions. A recent study among
older Americans indicates that social disconnectedness
predicted subsequent perceived isolation, whereas feelings of loneliness or isolation increased the risk of depression.50 Similarly, our findings suggest that patients with
CCLE may isolate themselves to cope with their perceptions of stigmatisation, which may lead to psychological
distress, more profound isolation and depression. Recent
findings also suggest that higher perceived social support
may lower the risk of psychological distress in patients
with psoriasis.16 Although depressed patients in our
study reported lower emotional support, having higher
emotional support did not buffer the effect of social isolation on depression. This finding is perhaps less surprising
when considering that the prevalence of depression did
not differ by marital status. However, in the multivariate
models, the slope of depression increased significantly
(approximately 4.5–5.1 points higher) in participants
who reported never being married, compared with those
currently married. These findings taken together suggest
that marriage itself might provide greater combined
resources and social support,51 whereas stigma is a process
of social devaluation causing diminished self-esteem and
social isolation. More sensitive measurement instruments
and complex interventions may be needed among those
who already have internalised stigma.
Patients with generalised DLE (lesions above and below
the neck) did have a significantly higher rate of depression, compared with those with localised DLE (lesions
above the neck). However, in the multivariate analysis,
we did not find a significant linear association between
having lesions above and below the neck and depression
scores. Moreover, the association between depression and
the main exposures remained similar for the whole CCLE
sample when the DLE subtype was excluded as a covariate.
These data support the complex pathways implicated in
the psychological impact of living with CCLE.
Younger age was independently associated with depression in our cohort, paralleling the age-related psychological vulnerability described in the general population.52
We also found a significant relationship between depression and self-reported physical health; however, neither
skin activity nor damage showed a significant correlation with depression in a subset of 59 CCLE participants who had CLASI scores. Thus, our data support
8

the multifactorial nature of depression in patients with
CCLE, suggesting that patients perceptions may play a
more critical role than clinical factors.53 Interestingly, in
a Latino population, perceived discrimination was found
to be inversely associated with self-
reported physical
health, and depression partially accounted for the association.54 Longitudinal studies are warranted to determine
whether depressive symptoms in patients with CCLE are
primarily driven by perceived stigmatisation and reduced
social connections, which in turn can lead to physical and
functional impairment, perpetuating the maladaptive
response.
Our study has limitations. First, the cross-
sectional
design does not allow causal interpretations or to assess
a temporal precedence of the mediation. This study
also relies on self-report measures, which have known
limitations. However, we used validated patient-reported
outcomes measures, which have been called for by the
WHO and NIH to allow the participants to characterise
their experience, perceptions and outcomes of living with
a disease.55 The population-based nature of the cohort
also limited our ability to clinically assess all participants
for skin activity and damage, which may lead to depression. However, we did not find a significant linear association between either CLASI activity or CLASI damage and
depression scores in a subset of 59 participants. These
results are consistent with previous findings indicating
a poor correlation between physician-rated severity and
psychiatric morbidity in dermatological outpatients.53
However, because the CLASI-scored subset was a small
sample size, our results cannot be generalised to the rest
of the cohort. We were able to explain 72% of variance
in depression; however, we cannot exclude residual and
unmeasured confounding. Moreover, our findings may be
confounded by the order and function of the constructs
in the regression models. The constructs were analysed
based on the assumption that stigma, social isolation
and emotional support have a critical role in depression
among individuals with CCLE. Our results are applicable
to a predominantly Black CCLE sample from the Southeastern USA and cannot be generalised to other populations. Future longitudinal studies can help to elucidate
the causal direction of the associations that we found and
provide context for understanding psychosocial pathways
and mental health in patients with CCLE.
Our study also has several strengths, including extending
the literature by focusing our analyses on patients with
CCLE. Prior studies included patients with all CLE types;
consequently, the burden and pathways of psychological distress in those with CCLE remained unknown.
Second, in contrast to previous studies, which predominantly involved White patients, we examined a largely
Black cohort of individuals with primary CCLE. Blacks
have higher susceptibility to CCLE,5 but these patients,
particularly those with DLE, also have more noticeable
ear and scalp dyspigmentation and scarring alopecia
than Whites.56 Therefore, the psychological impact may
be greater in this population. Third, as opposed to other
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academic-
based cohorts, our CCLE participants were
recruited from multiple sources, including community
practices, allowing us to conduct a ‘real-
world’ assessment. Fourth, by focusing on people with CCLE without
SLE, we were able to reduce the confounding effect of
SLE manifestations on depression. Fifth, our study is
the first to our knowledge to propose, test and provide
initial evidence for psychosocial pathways to depression in a largely Black population with primary CCLE,
creating opportunities for both confirmatory research
and upstream interventions.
In conclusion, our findings underscore that people
living with CCLE are at risk for experiencing adverse
effects of stigma, social isolation and depression and
present a theoretical model explaining potential pathways in the relationships between these psychosocial
effects. In addition to providing a blueprint for longitudinal research to test this promising model, these findings are essential to inform clinical, social and individual
interventions. Healthcare workers serving patients with
CCLE should be aware of the high prevalence of stigma,
social isolation and depression in this population and be
trained to conduct early screenings and referrals to mental
health services. Ideally, these findings could delay, reduce
or prevent depression in this population by pushing interventions upstream to when patients are experiencing
‘warning signs’ of stigma and social isolation. Campaigns
to educate patients’ family members and friends as well
as the general public about the disease are needed as a
parallel effort to reduce sources of social stigma. Moreover, psychoeducation and peer support may help reduce
internalised stigma, enhance social interactions and minimise the psychosocial impact of living with these visible
conditions.
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Supplemental Table 1. Baron & Kelly steps to test the mediation hypothesis
Baron & Kelly
Regression Analysis
Visual illustration
Step 1
Outcome variable Y (Depression) regressed on
X
Y
independent variable X (Stigma) to test path c
c
Step 2
Mediator variable M (Social isolation) regressed on
X
M
independent variable X (Stigma) to test path a
a
Step 3
Outcome variable Y (Depression) regressed on mediator
M
Y
variable M (Social isolation) to test path b
b
Step 4*
Outcome variable Y (Depression) regressed on
M
independent variable X (Stigma) and mediator variable
a
b
M (Social isolation) to test path c’
X
Y
c’
The three main measures used in the study to follow the Baron & Kelly procedures are indicated within
parentheses. *After the mediator variable is entered in the regression model, the relationship between the
independent and outcome variables should either disappear (full mediation) or significantly diminish (partial
mediation).

Supplemental Table 2. Description of Participants by CLASI assessment
Characteristics
Age at survey (years)
Disease duration (years)
Sex, n (%)
Race, n (%)
Education (years)
Marital status, n (%)

Work status, n (%)

Insurance status, n (%)
Depression T-score
Stigma T-score
Social Isolation T-score
Emotional support T-score

Indicator
Mean ± SD
Mean ± SD
Male
Female
BlackAA
White
Mean ± SD
Curently married
Ever married
Never married
Full- or part-time
Out of labor force
Unemployed/disabled
No insurance
Federal insurance
Private insurance
Mean ± SD
Mean ± SD
Mean ± SD
Mean ± SD

Overall
(n=121)
54.1 ± 13.8
14.2 ± 10.0
15 (12.4)
106 (87.6)
103 (85.1)
18 (14.9)
14.5 ± 3.1
38 (31.4)
43 (35.5)
40 (33.1)
48 (41.4)
31 (26.7)
37 (31.9)
21 (17.6)
62 (52.1)
36 (30.3)
53.9 ± 12.2
51.3 ± 10.4
49.8 ± 11.3
51.7 ± 8.9

CLASI Assessment
No (n=62) Yes (n=59)
55.9 ± 14.4 52.2 ± 13.0
14.8 ± 9.8
13.6 ± 10.2
10 (16.1)
5 (8.5)
52 (83.9)
54 (91.5)
48 (77.4)
55 (93.2)
14 (22.6)
4 (6.8)
14.7 ± 2.9
14.2 ± 3.4
21 (33.9)
17 (28.8)
21 (33.9)
22 (37.3)
20 (32.3)
20 (33.9)
23 (38.3)
25 (44.6)
18 (30.0)
13 (23.2)
19 (31.7)
18 (32.1)
4 (6.7)
17 (28.8)
33 (55.0)
29 (49.2)
23 (38.3)
13 (22.0)
57.2 ± 16.0 53.7 ± 12.0
49.5 ± 10.0 53.1 ± 10.5
48.8 ± 10.7 50.8 ± 11.9
52.1 ± 8.4
51.2 ± 9.5

P-value
0.1
0.5
0.2
0.02
0.4
0.8

0.7

0.004
0.6
0.06
0.3
0.6
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Supplemental Table 3. Multivariate Regression Analysis of Depression by Stigma, Social Isolation,
and Emotional Support: Developing Models
Model 1
Model 2
Model 3
Model 4
Factor
b (95% CI)
b (95% CI)
b (95% CI)
b (95% CI)
Primary exposures
0.75 ( 0.62, 0.89) 0.44 ( 0.23, 0.66) 0.12 (-0.14, 0.39) 0.12 (-0.14, 0.39)
Stigma
Social isolation
0.40 ( 0.19, 0.62) 0.40 ( 0.19, 0.62)
Emotional support
-0.00 (-0.17, 0.17)
Covariates
Sociodemographics
Sex (ref: male)
-0.35 (-4.61, 3.92) -1.69 (-6.00, 2.62) -1.66 (-5.67, 2.35) -1.66 (-5.73, 2.42)
Race (ref: white)
3.08 (-0.67, 6.83) 1.15 (-3.72, 6.01) 1.99 (-2.56, 6.54) 1.99 (-2.59, 6.57)
Age at survey (years)
-0.02 (-0.14, 0.11) -0.03 (-0.17, 0.11) 0.08 (-0.06, 0.23) 0.08 (-0.06, 0.23)
Education (years)
0.24 (-0.27, 0.75) 0.53 ( 0.01, 1.06) 0.40 (-0.10, 0.89) 0.40 (-0.10, 0.90)
Marital status (ref: currently married)
Ever married
2.66 (-0.81, 6.13) 3.78 ( 0.11, 7.44) 1.13 (-2.56, 4.82) 1.13 (-2.69, 4.94)
Never married
2.21 (-1.30, 5.73) 4.49 ( 0.80, 8.18) 4.80 ( 1.37, 8.24) 4.80 ( 1.33, 8.28)
Work status (ref: employed)
Out of labor force
-0.17 (-4.09, 3.75) -0.85 (-5.13, 3.43) -1.94 (-5.97, 2.08) -1.94 (-6.00, 2.12)
Unemployed/unable to work
0.62 (-3.05, 4.28) 0.04 (-3.74, 3.82) 0.37 (-3.15, 3.89) 0.37 (-3.18, 3.92)
Disease-related factors
DLE subtype (ref: below the neck)
Above and below the neck
-1.39 (-4.67, 1.89) -0.69 (-3.77, 2.38) -0.70 (-3.82, 2.43)
Skindex 29+3
Symptoms
0.04 (-0.05, 0.13) 0.04 (-0.04, 0.12) 0.04 (-0.04, 0.13)
CLE domain
0.06 (-0.02, 0.14) 0.04 (-0.03, 0.12) 0.04 (-0.03, 0.12)
Physical health (T-score)
-0.36 (-0.58, -0.13) -0.29 (-0.51, -0.08) -0.29 (-0.51, -0.08)
Current treatment
Hydroxychloroquine
0.43 (-2.64, 3.51) 1.54 (-1.38, 4.45) 1.54 (-1.42, 4.50)
Local steroids
-0.74 (-3.74, 2.26) -0.56 (-3.35, 2.23) -0.56 (-3.39, 2.27)
Systemic steroids/immunosuppressors
-1.86 (-5.61, 1.90) -1.34 (-4.85, 2.16) -1.34 (-4.87, 2.19)
0.672
0.720
0.720
(R-Square)
0.586
72.0%
71.4%
Percentage mediated
<0.001
<0.001
Sobel test
Models were tested among 101 participants with DLE; 8 DLE participants had missing data on 1 or more variables.
Abbreviations: b=beta coefficient; CI=confidence intervals; bolded values indicate statistical significance (95% CI no crossi ng 0).
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Supplemental Figure 1. Relationship between depression and skin
activity in 59 participants with primary chronic cutaneous lupus
erythematosus. Depression was measured with the PROMIS Depression
SF 8a and values are expressed as T-scores. Skin activity was measured
with the Cutaneous Lupus Erythematosus Disease Area and Severity
Index (CLASI-A; range 0-70).

Supplemental Figure 2. Relationship between depression and skin
damage in 59 participants with primary chronic cutaneous lupus
erythematosus. Depression was measured with the PROMIS Depression
SF 8a and values are expressed as T-scores. Skin damage was measured
with the Cutaneous Lupus Erythematosus Disease Area and Severity
Index (CLASI-D; range 0-56).
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